Zur Rose Group including Medpex/Apotal                            1,751.9         1,568.7  11.7% 
Zur Rose Group including Medpex/Apotal, in local currency                                  14.4% 
Zur Rose Group                                                    1,476.9         1,355.5   8.9% 
Zur Rose Group, in local currency                                                          11.4% 
Markets 
Germany including Medpex/Apotal                                   1,096.2           976.0  12.3% 
Germany including Medpex/Apotal, in local currency                                         16.5% 
Germany                                                             821.2           762.8   7.7% 
Germany, in local currency                                                                 11.7% 
Switzerland                                                         593.1           553.7   7.1% 
Rest of Europe                                                       66.4            39.7  67.3% 
Europe, in local currency                                                                  73.5% 
Business models 
B2C including Medpex/Apotal                                       1,236.2         1,106.2  11.7% 
B2C                                                                 961.1           893.1   7.6% 
Professional Services                                               453.1           422.8   7.2% 
Marketplace                                                          66.4            39.7  67.3% 
Revenue, in CHF million (unaudited)                       1.10.-31.12.2020 1.10.-31.12.2019 Change 
Zur Rose Group including Medpex/Apotal                               506.7            412.0  23.0% 
Zur Rose Group including Medpex/Apotal, in local currency                                    23.6% 
Zur Rose Group                                                       410.4            355.2  15.5% 
Zur Rose Group, in local currency                                                            15.9% 
Markets 
Germany including Medpex/Apotal                                      330.9            256.3  29.1% 
Germany including Medpex/Apotal, in local currency                                           29.8% 
Germany                                                              234.6            199.5  17.6% 
Germany, in local currency                                                                   18.0% 
Switzerland                                                          158.2            143.9  10.0% 
Rest of Europe                                                        18.8             11.8  59.5% 
Europe, in local currency                                                                    60.3% 
Business models 
B2C including Medpex/Apotal                                          369.4            291.9  26.5% 
B2C                                                                  273.0            235.1  16.1% 
Professional Services                                                119.7            107.7  11.2% 
Marketplace                                                           18.8             11.8  59.5% 

The elimination of revenue between markets and business models is not shown separately.

Investors and analyst contact Christoph Herrmann, Head of Investor Relations Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact Lisa Lüthi, Head of Group Communications Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda 18 March 2021 2020 Full-Year Results 20 April 2021 First Quarter Trading Update 29 April 2021 Annual General Meeting 19 August 2021 Half-Year Results 21 October 2021 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2020 it generated revenue of CHF 1,752 million (including Medpex and Apotal) and currently has 10.5 million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.

^[1] As the separation of the mail-order business has not yet been completed, Medpex and Apotal had only a minor impact on the consolidated revenue of the Zur Rose Group. ^[2] Customers supplied by the Zur Rose Group, either directly or through its partners. -----------------------------------------------------------------------------------------------------------------------

End of Media Release -----------------------------------------------------------------------------------------------------------------------


Language:     English 
Company:      Zur Rose Group AG 
              Walzmühlestrasse 60 
              8500 Frauenfeld 
              Switzerland 
Phone:        +41 52 724 08 14 
Internet:     www.zurrosegroup.com 
ISIN:         CH0042615283 
Listed:       SIX Swiss Exchange 
EQS News ID:  1162093 
 
End of News   EQS Group News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 21, 2021 01:02 ET (06:02 GMT)